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Background: It is hypothesised that individuals with knowledge of their genetic risk are more likely to make
health-promoting dietary and lifestyle changes. The present study aims to test this hypothesis using data from the
Food4Me study. This was a 6-month Internet-based randomised controlled trial conducted across seven centres in
Europe where individuals received either general healthy eating advice or varying levels of personalised nutrition
advice. Participants who received genotype-based personalised advice were informed whether they had the risk
(CT/TT) (n = 178) or non-risk (CC) (n = 141) alleles of the methylenetetrahydrofolate reductase (MTHFR) gene in
relation to cardiovascular health and the importance of a sufficient intake of folate. General linear model analysis
was used to assess changes in folate intake between the MTHFR risk, MTHFR non-risk and control groups from
baseline to month 6 of the intervention.
Results: There were no differences between the groups for age, gender or BMI. However, there was a significant
difference in country distribution between the groups (p = 0.010). Baseline folate intakes were 412 ± 172, 391 ± 190
and 410 ± 186 μg per 10 MJ for the risk, non-risk and control groups, respectively. There were no significant
differences between the three groups in terms of changes in folate intakes from baseline to month 6. Similarly,
there were no changes in reported intake of food groups high in folate.
Conclusions: These results suggest that knowledge of MTHFR 677C→ T genotype did not improve folate intake in
participants with the risk variant compared with those with the non-risk variant.
Trial registration: ClinicalTrials.gov NCT01530139
Keywords: MTHFR, Methylenetetrahydrofolate reductase 677C→ T genotype, Genetic risk knowledge, Folate,
Personalised nutrition* Correspondence: eileen.gibney@ucd.ie
1Institute of Food & Health, University College Dublin, Dublin 4, Ireland
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
O’Donovan et al. Genes & Nutrition  (2016) 11:25 Page 2 of 9Background
The completion of the human genome sequence in the
early 2000s promised to revolutionise healthcare through
the identification of individuals at increased risk of many
complex diseases [1]. Furnished with knowledge of their
genotype, it was hypothesised that these individuals would
be more likely to make health-promoting changes to
ameliorate their risk of disease [2]. To date, a number of
studies have investigated the effect of genetic knowledge
on changes in lifestyle behaviours in relation to chronic
diseases [3–6]. In the REVEAL trial, the investigators re-
ported that in those individuals with a family history of
Alzheimer’s disease (AD), knowledge of an APOE ɛ4+ risk
genotype was positively associated with dietary supple-
ment use [4]. Hendershot and colleagues reported similar
effects in relation to alcohol-related cancer risk [7] while
others have reported no effect on dietary and lifestyle be-
haviours in those at risk of breast cancer [8], familial
hypercholesterolaemia [9] or diabetes [5].
Following on from this, few studies have examined the
impact of genetic knowledge in relation to specific
changes in dietary intakes [10, 11]. In relation to the
APOE genotype, individuals who were told that they had
the ɛ4+ risk genotype were found to improve their diet-
ary fat quality more than those individuals with the ɛ4−
genotype and control group [10]. Nielsen and El-Sohemy
reported a significant reduction in sodium intakes in in-
dividuals who were informed they had the risk version
of the ACE gene compared with those who were given
healthy eating advice (p = 0.008) [11]. A recent Cochrane
review concluded that communicating genotype-based
disease risk estimates does not change behaviour in
terms of smoking and lifestyle; however, the authors did
note a small effect in relation to changes in dietary in-
take [12, 13]. Therefore, the evidence is mixed and it is
still unclear whether knowledge of genotype may pro-
mote changes in diet and lifestyle.
This paper examines the impact of methylenetetrahydro-
folate reductase (MTHFR) genotype disclosure on changes
in dietary folate as an example of the potential influence of
genomic testing on changes in lifestyle behaviours.
MTHFR catalyses the conversion of 5,10-methylenetetra-
hydrofolate to 5-methyltetrahydrofolate, which conse-
quently results in the recycling of homocysteine to
methionine in the methylation cycle. The 677C→T poly-
morphism in MTHFR results in three alleles (CC, CT and
TT). When compared with normal homozygous variants
(677CC), heterozygous (677CT) variants have only 65 %
enzyme activity levels and homozygotes (TT) have 30 %
enzyme activity [14] which results in decreased circulating
folate concentrations; specifically, 10 % lower in heterozy-
gotes and 18 % lower in homozygotes [15].
Because of the lowering effect on plasma homocysteine
concentrations, it has been hypothesised that higherintakes of folate and related B vitamins may reduce car-
diovascular disease (CVD) risk [16]. Epidemiological stud-
ies have predicted that a 3 μmol/L reduction in serum
concentration of homocysteine would decrease the risk of
coronary heart disease by 11–16 % [17]. However, a recent
Cochrane review found no evidence of a positive effect on
CVD risk of homocysteine-lowering interventions through
supplementation with folate and other B vitamins on
CVD [18]. Others have suggested that the beneficial effect
of such supplementation will be apparent only in certain
population groups with low folate status [19]. Further-
more, supplementation may reduce the risk of stroke ra-
ther than other aspects of CVD [20]. Based on these
findings, individuals with the risk variants of the MTHFR
gene (CT and TT) may require higher folate intakes to
lower homocysteine concentrations and reduce their CVD
risk. The aim of this study was to investigate the influence
of knowledge of personalMTHFR genotype on changes in
folate intake in participants taking part in the Food4Me
study (ClinicalTrials.gov number: NCT01530139).
Methods
Study design and ethical approval
The Food4Me proof-of-principle (PoP) study was a
6-month Internet-based RCT which aimed to investigate
the effect of personalised nutrition advice on health-related
outcomes compared with generic healthy eating advice
[21]. This study mimicked an online personalised nutrition
service where all communication between trained nutri-
tionists and the participants was done via post or electron-
ically and no face-to-face contact took place. Participants
were randomised to one of the four treatment groups: level
0 (control group) received non-personalised dietary advice
based on standardised European healthy eating guidelines,
level 1 received personalised dietary advice based on indi-
vidual dietary intake data alone, level 2 received persona-
lised dietary advice based on dietary intake and phenotypic
markers and level 3 received personalised dietary advice
based on dietary intake, phenotypic markers and genotype
data. Participants received feedback at 0, 3 and 6 months. A
more detailed description of the study protocol has previ-
ously been published [21]. Ethical approval was obtained
from Research Ethics Committees at the seven participating
centres. The study was registered at clinicaltrials.gov (ref
NCT01530139). Participants were recruited via the
Food4Me website (www.food4me.org) by posters, radio ad-
vertisements, leaflets and social media. The recruitment
and screening processes have been reported elsewhere [21].
Participants provided informed written consent prior to
participation.
Data collection
All data were self-collected, with participants receiving
detailed guidelines on how to collect the data. Data on
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food frequency questionnaire (FFQ) which included food
items frequently consumed in each of the seven coun-
tries. This FFQ was developed and validated [22, 23]
specifically for the Food4Me study. To identify possible
under-reporting, basal metabolic rate (BMR) was calcu-
lated using the Henry equation [24] and multiplied by a
PAL factor of 1.1 using the Goldberg cutoffs [25] to de-
termine each individual’s lowest possible estimated en-
ergy requirements (EER) when in energy balance.
Under-reporting was defined as reported energy intakes
below this EER unless participants were following a
weight loss diet. Over-reporting was defined as reported
energy intakes of greater than 4500 cal [22].
Anthropometric measures included weight (kg), height
(m) and waist, hip and thigh circumferences [21]. Buccal
cell samples were collected at baseline using a Isohelix
SK-1 DNA buccal swab and Isohelix dri-capsule and
analysed by LCG Genomics (Hertfordshire, United
Kingdom) using KASP™ genotyping assays to provide
bi-allelic scoring of single nucleotide polymorphisms
(SNPs).MTHFR was one of a panel of 33 nutrition-related
SNPs measured [21]. Participants were given feedback
relating to five key SNPs includingMTHFR.
Personalised feedback
Participants randomised to levels 1, 2 and 3 received
personalised reports via email, using decision trees for
the delivery of systematic tailored dietary advice, from
trained nutritionists across seven centres, on dietary,
physical activity, phenotypic and genotypic information
as appropriate to each group level [21]. These persona-
lised reports were designed based on behaviour change
techniques [26, 27]. For example, the first section of the
report begun with “a message from your nutritionist”
which was a personalised motivating message to encour-
age the participant to make the relevant dietary and life-
style changes [28].
Within the report, participants received feedback on
their dietary intake and phenotype information using a
gradation scale where green indicated “good, no change
recommended,” amber indicated “improvement needed”
and red indicated “improvement strongly recom-
mended.” Participants in level 3 were informed whether
they had a particular “risk” version of the MTHFR gene
as indicated by “yes” or “no” where risk versions were ei-
ther of the CT or TT genotypes and non-risk genotype
was CC. Participants were informed about the relation-
ship between variants in this gene and their dietary fol-
ate needs. With respect to the MTHFR risk genotype,
participants were informed that “People with a specific
variation of this gene can benefit by increasing their in-
take of the vitamin folate. Increasing folate intake (found
in green leafy vegetables) has been associated with animprovement in factors relating to cardiovascular health
in these individuals.”
The final section of the report contained a personalised
goals section including three individualised nutrient-
related goals derived from dietary, phenotypic or ge-
notypic information as appropriate to the intervention
group. These nutrient-related goals were selected by a
pre-defined nutrient ranking system where nutrients that
most warranted change were prioritised [28]. For those in
level 3, participants with a MTHFR risk genotype and in-
adequate intakes of folate were advised to increase their
folate intake, e.g. “Your total folate intake is below the rec-
ommended levels. It is really important for you to increase
your folate intake because you have a genetic variation
that can benefit by increasing your folate intake.” In con-
trast, those participants with a MTHFR risk genotype and
with adequate intakes of folate were given a positive mes-
sage, i.e. “Your total folate intake is within the recom-
mended levels. You are doing really well because this is a
result of your consumption of food rich in folate. We
strongly recommend maintaining this level of consump-
tion of foods rich in folate because you have a genetic
variation that can benefit from increasing your folate in-
take. Well done!” As part of the nutrient-related goals
message, participants were also given information on the
sources of folate rich foods and tips on how to increase
their consumption such as eating more dark green leafy
vegetables, eating fortified breakfast cereals and adding
beans and pulses to salads.
To aid participants’ understanding of genetic risk, add-
itional information was provided to participants on
topics such as “what is a genotype” and “how can some
genes influence your health status.” This supplementary
material was sent in the same email as the personalised
reports.
For the purposes of this study, only level 3 participants
(who received information about their genotype) and con-
trol (level 0) participants are included with changes in
dietary intake between 0 and 6 months as the main out-
come. For secondary analysis, those participants in level 3
are compared with those in levels 1 and 2 who received
personalised advice without genotype information.
Statistics
Data was analysed using SPSS software version 20 (SPSS
Inc. Chicago, Il, USA). Participants were split into
MTHFR “risk” (CT, TT genotypes) and MTHFR “non-
risk” (CC genotype) groups and compared with the con-
trol group. Following the 6-month intervention, 21 % of
individuals who took part in the Food4Me study were
lost to follow-up while 8 % dropped out immediately
after being randomised. Drop-outs at months 0, 3 and 6
were removed. Descriptive statistics (means and stand-
ard deviations) were performed to characterise the
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egorical variables. ANOVAs were performed to investi-
gate the baseline characteristics. As the data were not
normally distributed, variables were log transformed and
analysis performed on the log values. General linear
models were used to investigate differences between the
groups concerning changes in folate intake from baseline
to month 6 (and month 3) controlling for baseline folate
intakes and country where necessary.
To address the research question “Does knowledge of
MTHFR genotype improve folate intake more in those
with risk version of the gene compared with those with
the non-risk version of the gene and those who received
general healthy eating advice (i.e. control group),” the fol-
lowing analysis was conducted: (1) the change in folate in-
take from month 0 to month 6 for all participants in the
MTHFR risk, MTHFR non-risk and control groups; (2)
the change in folate intake from month 0 to month 6 be-
tween the control group and those in the MTHFR risk
and MTHFR non-risk groups restricted to those who re-
ceived a folate-related goal (i.e. those who were told that
they needed to increase their folate intake and those who
were told to maintain their current folate intakes) and (3)
the change in folate intake from month 0 to month 6 be-
tween the control group and those in the MTHFR risk
andMTHFR non-risk groups restricted to those who were
told that they needed to increase their folate. Fisher’s least
significant difference (LSD) post hoc analysis was used to
investigate inter-group differences. As secondary analysis,
it was also investigated whether personalised advice based
on MTHFR risk knowledge was more effective in motivat-
ing changes in dietary folate compared with those whoTable 1 Baseline characteristics of MTHFR risk, MTHFR non-risk and c
Demographical information MTHFR Risk (CT/TT) (n = 178) M
Age (years) 42 ± 13 4
Gender (M/F) 71/107 6
Weight (kg) 75.1 ± 15.4 7
BMI (kg/m2) 25.5 ± 4.9 2
W.C. (m) 0.86 ± 0.13 0
Frequency % (n)b
Germany 19.1 (34) 7
Greece 17.4 (31) 1
Ireland 10.7 (19) 1
Netherlands 16.3 (29) 1
Poland 8.4 (15) 1
Spain 16.3 (29) 1
UK 11.8 (21) 1
Excludes drop-outs at months 3 and 6
W.C. waist circumference
aBaseline characteristics presented as means ± standard deviations and differences
exception of gender and country where chi-square analysis was used
bFrequency of country was assessed across the MTHFR risk and MTHFR non-risk groreceived personalised advice with noMTHFR genotype in-
formation. To examine the effect of personalisation of
dietary advice on changes in dietary folate, differences be-
tween the control group, level 1 group and level 2 group
were also assessed. All analyses were repeated using data
for valid reporters only, i.e. after removal of under-
reporters and over-reporters as defined previously.
Results
Baseline characteristics of the MTHFR risk (CT/TT), MTHFR
non-risk (CC) and control groups
There were no differences between the risk, non-risk
and control groups in terms of age and anthropometric
measures (Table 1). All groups had a BMI that was
slightly above the normal BMI range (25.5 ± 4.9, 26.0 ±
4.9 and 25.1 ± 4.4 kg/m2, respectively), and there was no
difference in gender distribution between the groups.
Distribution of the risk and non-risk groups were signifi-
cantly different across the countries (p = 0.010) (Table 1).
The frequency of the MTHFR risk variant was the high-
est in Germany and the lowest in Poland. Overall, the
genotype frequencies (CC, CT, TT) were within the
Hardy Weinburg Equilibrium (results not shown). In-
takes of energy, folate and major folate-containing foods
for each of the three groups at month 0 and month 6
are given in Table 2. At baseline, folate intakes for the
risk, non-risk and control groups were similar at 412 ±
172, 391 ± 190 and 410 ± 186 μg per 10 MJ of energy, re-
spectively. One outlier was removed from the analysis
due to consumption of a medically prescribed high folate
supplement (>5000 mcg) between months 3 and 6.ontrol groups
THFR Non-risk (CC) (n = 141) Control (n = 309) p valuea
1 ± 14 40 ± 13 0.526
8/73 130/179 0.304
6.5 ± 16.1 73.77 ± 15.02 0.216
6.0 ± 5.0 25.1 ± 4.4 0.138
.88 ± 0.14 0.85 ± 0.13 0.129
.8 (11) 0.010
3.5 (19)
7.1 (24)
7.7 (25)
5.6 (22)
1.3 (16)
7.0 (24)
between the groups were investigated using ANOVA for all variables with the
ups only
Table 2 Comparison of dietary intakes for the MTHFR risk, MTHFR non-risk and control groups at M0 and M6
MTHFR risk (CT/TT) Number MTHFR non-risk (CC) Number Control Number p valuea
Energy (kJ) M0 10,201 ± 3423 178 11,558 ± 5479 141 10,617 ± 4810 309 0.203
M6 8810 ± 2968 178 9637 ± 3675 141 9605 ± 4132 309
Folate (μg per 10 MJ) M0 412 ± 172 178 391 ± 190 141 410 ± 186 309 0.131
M6 427 ± 193 178 410 ± 168 141 410 ± 210 309
Liver (g) M0 1 ± 3 178 2 ± 9 141 1 ± 3 309 0.162
M6 1 ± 4 178 1 ± 4 141 1 ± 3 309
Poultry (g) M0 33 ± 42 144 37 ± 40 130 30 ± 29 270 0.136
M6 33 ± 32 144 32 ± 28 130 32 ± 52 270
Shellfish (g) M0 4 ± 7 178 3 ± 7 141 3 ± 5 309 0.430
M6 4 ± 7 178 3 ± 6 141 3 ± 7 309
Green leafy veg (g) M0 49 ± 41 178 48 ± 44 141 45 ± 42 309 0.220
M6 53 ± 50 178 49 ± 45 141 46 ± 48 309
Fortified cereals (g) M0 22 ± 33 178 20 ± 31 141 19 ± 27 309 0.444
M6 22 ± 30 178 20 ± 24 141 20 ± 26 309
Beans and legumes (g) M0 22 ± 34 144 27 ± 34 130 25 ± 44 270 0.726
M6 20 ± 23 144 26 ± 48 130 21 ± 31 269
Excludes drop-outs at months 3 and 6
M0 month 0, M6 month 6
aValues presented as means ± standard deviations. All analysis was conducted on log-transformed values. General linear models were used to assess the impact of
group on month 6 intake with M0 as a covariate and controlling for country where necessary
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Dietary folate intakes increased from 412 ± 172 μg per
10 MJ to 427 ± 193 μg per 10 MJ in the MTHFR risk
group and from 391 ± 190 μg per 10 MJ to 410 ± 168 μg
per 10 MJ in the MTHFR non-risk whereas no increase
was observed in the control group. Although both inter-
vention groups (risk and non-risk) increased their folate
intakes in comparison with the control, there were no
significant differences between the groups (p = 0.131).
There were no significant differences between the risk,
non-risk or control with respect to changes in reported
intakes of food groups high in folate (Table 2). Similarly,
there were no differences in frequency of folate supple-
ment users between the groups at any of the time points
(data not shown). Table 3 illustrates the dietary intakes
of those individuals who received a folate-related goal
(i.e. those who were advised to increase their folate in-
take and those who were advised to maintain their
current folate intakes) compared with the control group.
Post hoc analysis revealed a significant (p = 0.033) differ-
ence between the non-risk and control groups for
change in folate intake from baseline. No significant dif-
ferences were observed between the groups with respect
to changes in intakes of food groups containing folate.
Table 4 summarises the folate intakes of those individ-
uals who were advised specifically to increase their folate
intake compared with the control group. There were no
significant differences between the groups for changes in
folate intakes or of folate-containing food groups.Given the significant difference between the groups in
terms of the MTHFR genotype frequency, the change in
folate intakes was also investigated per country and no sig-
nificant differences were found. Changes in dietary folate
intakes between month 0 and month 3 were also investi-
gated (Additional file 1: Table S1, S2 and S3). Overall, no
significant differences were found between the groups. No
differences were also found when those in the MTHFR risk
and MTHFR non-risk groups were compared with those
who received personalised advice without information on
MTHFR genotype (Additional file 1: Table S4 and S5). No
differences were observed between the control, level 1 and
level 2 groups in terms of changes in dietary folate intakes
from baseline to month 3 or month 6 (data not shown). All
of the analyses were repeated for “valid” dietary reporters
(i.e. after exclusion of both over- and under-reporters), and
similar results were observed (data not shown).
Discussion
This study demonstrated that knowledge of carriage of
the risk variant (CT, TT) for the MTHFR 677C→T
genotype did not improve folate intake compared with
participants with the non-risk variant (CC) in the
Food4Me study. These findings add to the current litera-
ture regarding disclosure of genotype-based advice.
The evidence supporting the benefits of genetic risk
knowledge is mixed, with some studies demonstrating a
benefit of genetic knowledge in motivating lifestyle
changes [4, 11, 29, 30] and others reporting no
Table 4 Dietary intakes by MTHFR risk and MTHFR non-risk participants who were told to increase their folate intake compared with
those who received general healthy eating advice (control group)
MTHFR risk (CT/TT) Number MTHFR non-risk (CC) Number Control Number p valuea
Energy (kJ) M0 8620 ± 2708 83 8939 ± 2879 55 10,617 ± 4810 309 0.061
M6 7767 ± 2742 83 7842 ± 2237 55 9605 ± 4132 309
Folate (μg per 10 MJ) M0 361 ± 123 83 329 ± 81 55 410 ± 186 309 0.165
M6 385 ± 147 83 395 ± 175 55 410 ± 210 309
Liver (g) M0 1 ± 3 83 2 ± 4 55 1 ± 3 309 0.369
M6 2 ± 4 83 1 ± 4 55 1 ± 3 309
Poultry (g) M0 36 ± 53 66 27 ± 30 50 30 ± 29 270 0.072
M6 35 ± 28 66 25 ± 25 50 32 ± 55 270
Shellfish (g) M0 3 ± 6 83 3 ± 6 55 3 ± 5 309 0.092
M6 2 ± 3 83 2 ± 5 55 3 ± 7 309
Green leafy veg (g) M0 39 ± 38 83 38 ± 40 55 45 ± 42 309 0.261
M6 44 ± 33 83 42 ± 35 55 46 ± 48 309
Fortified cereals (g) M0 14 ± 19 83 11 ± 16 55 19 ± 27 309 0.469
M6 17 ± 21 83 14 ± 16 55 20 ± 26 308
Beans and legumes (g) M0 17 ± 17 66 19 ± 24 50 25 ± 44 270 0.146
M6 22 ± 22 66 27 ± 64 50 21 ± 31 269
Includes participants who were specifically advised to increase their folate intakes at month 0 and/or month 3 and where drop-outs at months 3 and 6
were excluded
M0 month 0, M6 month 6
aValues are presented as means ± standard deviations. All analysis was conducted on the log-transformed values. General linear models were used to assess the
impact of group on month 6 with M0 intake as a covariate and controlling for country where necessary
Table 3 Dietary intakes by MTHFR risk and MTHFR non-risk participants who received folate-related goal (i.e. those who were told
that they needed to increase their folate intake and those who were told to maintain their current folate intakes) compared with
those who received generic healthy eating advice (control group)
MTHFR risk (CT/TT) Number MTHFR non-risk (CC) Number Control Number p valuea
Energy (kJ) M0 9506 ± 3225 121 9013 ± 2873 57 10,617 ± 4810 309 0.325
M6 8589 ± 3028 121 7859 ± 2199 57 9605 ± 4132 309
Folate (μg per 10 MJ) M0 402 ± 156 121 330 ± 80 57 410 ± 186 309 0.033
M6 429 ± 198 121 398 ± 172c 57 410 ± 210n 309
Liver (g) M0 1 ± 3 121 2 ± 4 57 1 ± 3 309 0.074
M6 2 ± 4 121 1 ± 4 57 1 ± 3 309
Poultry (g) M0 34 ± 47 100 27 ± 29 52 30 ± 29 270 0.096
M6 34 ± 34 100 24 ± 25 52 32 ± 52 270
Shellfish (g) M0 4 ± 7 121 3 ± 6 57 3 ± 5 309 0.167
M6 3 ± 5 121 2 ± 5 57 3 ± 7 309
Green leafy veg (g) M0 46 ± 43 121 42 ± 43 57 45 ± 42 309 0.208
M6 49 ± 38 121 44 ± 36 57 46 ± 48 309
Fortified cereals (g) M0 23 ± 37 121 11 ± 15 57 19 ± 27 309 0.304
M6 24 ± 32 121 14 ± 16 57 20 ± 26 308
Beans and legumes (g) M0 22 ± 35 100 20 ± 24 52 25 ± 44 270 0.443
M6 22 ± 24 100 27 ± 63 52 21 ± 31 269
Includes participants who received folate as a target nutrient at month 0 and/or month 3 and excludes drop-outs at months 3 and 6
M0 month 0, M6 month 6
aValues are presented as means ± standard deviations. All analysis was conducted on the log transformed values. General linear models were used to assess the
impact of group on month 6 intake with M0 as a covariate and controlling for country where necessary. Superscript letters denote where the differences lie
between groups where superscript letter n means significantly different from the MTHFR non-risk group and superscript letter c means significantly different from
the control group
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investigated the effect of knowledge of genotype-based
risk on motivation to change lifestyle including diet with
respect to one specific disease, e.g. diabetes [5] or CVD
[3]. Grant and colleagues investigated the effect of gen-
etic risk testing and counselling on motivation to change
behaviours for the reduction of diabetes risk [5]. In this
trial, overweight patients at increased phenotypic risk of
diabetes were randomised to receive genetic testing or
not receive genetic testing, and then, both groups partic-
ipated in a 12-week diabetes prevention programme.
The investigators found that the genetic risk counselling
did not alter significantly self-reported motivation or ad-
herence to the prevention programme [5]. Taylor and
colleagues examined lifestyle changes among urban
African-American women following genetic counselling
for hypertension compared to baseline [3]. With the ex-
ception of sodium intake, changes in lifestyle behaviours,
blood pressure and pulse pressure readings did not differ
significantly from baseline [3]. The hypothesis that com-
municating risk of developing Crohn’s disease based on
genotype can motivate behaviour change among
smokers at familial risk was also investigated [33]. The
researchers found that the addition of genotypic infor-
mation when communicating risk for Crohn’s disease
based on family history and smoking status did not
affect motivation for behaviour change [33]. The results
of the present study are in line with these findings of a
lack of effect of knowledge of genotype-based risk.
However, in contrast, a recent study undertaken with
young adults in Canada observed a positive effect of dis-
closing genetic information on changes in diet [11]. In
this study, participants (n = 157) were genotyped for var-
iants that affect caffeine metabolism (CYP1A2), vitamin
C utilisation (GSTT1 and GSTM1), sweet taste percep-
tion (TAS1R2) and sodium-sensitivity (ACE). They were
then randomised to receive either personalised nutrition
advice based on individual genotype or generic healthy
eating guidance. After 3 months, there were no signifi-
cant dietary changes between the intervention and con-
trol groups, but at 12 months, participants with the risk
version of the ACE gene in the intervention group sig-
nificantly reduced their sodium intake compared with
the control group (p = 0.008). These findings may mean
that a longer time frame is needed to observe the added
benefit from genotype-based advice. In the Canadian
study, there were no significant changes for dietary tar-
gets other than salt perhaps because the participants
were already consuming intakes of those dietary compo-
nents in line with the recommendations [11].
The current study was part of the larger Food4Me
study which investigated the effect of varying levels of
personalised advice on motivating behaviour change
compared with generic healthy eating advice [21]. Itshould be noted that this study was not designed to
examine the effect of disclosure of MTHFR genotype
specifically and related dietary changes to folate. Since
each participant randomised to the personalised nutri-
tion group (levels 1–3) received three individualised
dietary goals, it is possible that participants could have
prioritised other aspects of their personalised dietary ad-
vice so the impact of the MTHFR-related advice was di-
minished. It is also likely that participants were more
interested in weight loss and healthy eating advice as ap-
proximately 50 % of the participants were overweight or
obese. Furthermore, dietary advice to reduce saturated
fat and salt intake and related health benefits would be
better known to participants from a public health point
of view in comparison with dietary advice to increase
folate to reduce CVD risk. This study was designed to
mimic an online personalised nutrition company where
tailored dietary advice was delivered via email by trained
nutritionists. Although additional information was pro-
vided to participants regarding genetic risk and related
dietary intake, it is possible that the online delivery of
the information may have affected participants’ under-
standing of their genetic results and personalised dietary
information which could have contributed to the un-
changed dietary behaviour observed. In addition, as
noted above, a longer time frame may be needed to re-
veal any additional effect of genotype-based advice [11].
The volunteers in the Food4Me study were recruited
on the basis that they were generally healthy. This is in
contrast to some other studies which have focused on
particular patient groups or those at increased pheno-
typic or familial disease risk. In the REVEAL trial, the in-
vestigators examined the effect of disclosure of APOE
genotype-based risk of AD on related lifestyle changes
[30]. The investigators reported that those with the
APOE4-positive genotype were significantly more likely
to report making an AD-specific health behaviour
change 1 year after disclosure compared to those who
were APOE4-negative (p = 0.02). In a follow-up study,
Vernarelli and colleagues reported that APOE4-positive
individuals with family history of AD were twice as likely
to report making a nutrition behaviour change than
those who were APOE4 negative with an increase in
supplement use among APOE4-positive participants [4].
However, in critique of the REVEAL study, Fanshawe
and colleagues drew attention to the fact that those who
were APOE4 positive also had a higher AD-risk score
based on family history so that the greater behaviour
may have been a consequence of information about
higher risk estimate and that genotypic information was
not the key motivator for behaviour change [34].
Whether individuals at increased risk of a particular dis-
ease are more responsive to genotype-based dietary ad-
vice per se remains an open question.
O’Donovan et al. Genes & Nutrition  (2016) 11:25 Page 8 of 9Strengths of this study include the randomised design and
the fact that it mimicked a personalised nutrition service
similar to those currently available. The main limitation of
the study is the use of a FFQ to quantify the changes in in-
takes of dietary folate. While FFQs are useful for examining
population level intakes, they are less good at examining in-
dividual dietary intakes and potentially, measures of circulat-
ing folate concentrations may be more sensitive in capturing
changes in folate intake [35]. Furthermore, the Food4Me
study was not designed to examine changes in specific nutri-
ents as participants were given a selection of nutrients to
change, and therefore, it would be challenging to identify
changes in any one particular nutrient. The population
studied could also have been a limitation as the personalised
nutrition advice was given to individuals free of charge, and
those who pay for such services may be more motivated to
make the relevant dietary and lifestyle changes.
Conclusions
In summary, the findings of this study suggest that
knowledge of MTHFR variant status did not influence
changes in dietary folate intake in response to a persona-
lised nutrition intervention. Our findings are similar to
those studies which showed no effect of genotypic infor-
mation on relevant dietary and lifestyle changes [5, 33].
Future work should be directed towards testing this hy-
pothesis in individuals at a known higher phenotypic or
familial risk of CVD and should include the measure-
ment of blood-based markers of folate status. Further-
more, it would be interesting to test this concept in a
general practitioner (GP) setting where face-to-face con-
tact between the individual and healthcare provider may
result in a different outcome compared with online de-
livery of personalised nutrition and lifestyle advice.
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